BMY Bristol Myers Squibb Company: Net earnings per share growth forecast for next year

Corporate emblem and logo of bms.com (BMY)

The time-series assessment of future earnings per share on the GURU.Markets chart demonstrates trends where 3.80 expresses the latest metric level. Bristol-Myers Squibb (BMY) is implementing "green chemistry" and ESG standards into its production. A stable roster of top oncology researchers supports the brand, although the risk of losing patent exclusivity is currently exerting pressure on the company's investment attractiveness.

BMY: Bristol Myers Squibb Company Net earnings per one share growth forecast for next year 07/04/2022 - 11/18/2026

Bristol Myers Squibb - analytical breakdowns and key metrics (BMY)

- share price and consensus valuation forecast:
Initial company analysis:BMY, bms.com
Core merchandise of bms.com

A conservative approach to analyzing Bristol-Myers Squibb (BMY) requires evaluating future cash flows through the lens of market expectations. This metric aggregates expert earnings per share (EPS) forecasts, reflecting the speed of business valuation adjustments during external shocks. The trend in the consensus EPS forecast demonstrates the resilience of sales margins for patented drugs in oncology and cardiology. The growth of this indicator confirms the investment attractiveness of Bristol-Myers Squibb (BMY) as a stable asset.